Results from this phase 2 clinical trial showed that the triple regimen consisting of SMET12, toripalimab and chemotherapy, showed manageable safety and anti-tumor action among advanced NSCLC patients positive for EGFR protein expression. Here, EGFR is linked to non-small cell lung carcinoma.